-+ 0.00%
-+ 0.00%
-+ 0.00%
Korro Bio Presents KRRO-121 Development Plan, Targets Interim Data in Second Half of 2027
Share
Listen to the news
Korro Bio Presents KRRO-121 Development Plan, Targets Interim Data in Second Half of 2027
  • Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027.
  • Interim KRRO-121 data are expected in the second half of 2027; a KRRO-111 regulatory submission is planned for the first half.
  • Cash runway extends into the second half of 2028, supporting multiple development milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending